ImmunoVaccine Technologies to Help Strengthen Canada's Defenses Against Biological Threats

May 15, 2009
BioPharm International Editors

ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), a vaccine development company, has signed a three-year research agreement with Defence Research and Development Canada (DRDC).

ImmunoVaccine Technologies, Inc. (IVT, Halifax, Nova Scotia), a vaccine development company, has signed a three-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT’s DepoVax vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.

Related Content:

News